Center for Clinical and Translational Science, University of Vermont, Burlington, VT 05405, USA.
J Biomed Inform. 2010 Jun;43(3):442-50. doi: 10.1016/j.jbi.2009.10.003. Epub 2009 Oct 20.
The centralized and public availability of molecular sequence and clinical trial data presents an opportunity to identify potentially valuable linkages across the bench-to-bedside "T1" translational barrier. In this study, we sought to leverage keyword metadata (Medical Subject Heading [MeSH] descriptors) to infer relationships between molecular sequences and clinical trials, as indexed by GenBank and ClinicalTrials.gov. The results of this feasibility study found that approximately 30% of sequences in GenBank could be linked to trials and over 90% of trials in ClinicalTrials.gov could be linked to sequences through MeSH descriptors. In a cursory evaluation, we were able to consistently identify meaningful linkages between molecular sequences and clinical trials. Based on our findings, there may be promise in subsequent studies aiming to identify linkages across the T1 translational barrier using existing large repositories.
分子序列和临床试验数据的集中和公开提供了一个机会,可以识别出跨越“T1”转化障碍的潜在有价值的联系。在这项研究中,我们试图利用关键字元数据(医学主题词 [MeSH] 描述符)来推断 GenBank 和 ClinicalTrials.gov 索引的分子序列和临床试验之间的关系。这项可行性研究的结果发现,GenBank 中的大约 30%的序列可以与试验相关联,而 ClinicalTrials.gov 中的超过 90%的试验可以通过 MeSH 描述符与序列相关联。在一个粗略的评估中,我们能够始终如一地识别出分子序列和临床试验之间有意义的联系。基于我们的发现,在使用现有大型存储库来识别 T1 转化障碍之间的联系的后续研究中可能有希望。